OncBioMune Pharmaceuticals, Inc. Announces Sales Results for the Period September 16, 2016 to February 16, 2017; Provides Sales Guidance for the Year 2017
March 27, 2017 at 02:30 pm
Share
OncBioMune Pharmaceuticals, Inc. announced sales results for the period September 16, 2016 to February 16, 2017. For the period, the sales were approximately USD 330,000, exceeding projections for USD 125,000 initially forecast for the first six months at product launch during the third quarter last year.
For the year 2017, the Company anticipates that sales efforts will continue to accelerate and anticipates combined sales in the range of USD 750,000 to USD 850,000 for the products in 2017.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
OncBioMune Pharmaceuticals, Inc. Announces Sales Results for the Period September 16, 2016 to February 16, 2017; Provides Sales Guidance for the Year 2017
THERALINK TECHNOLOGIES, INC. 